Nanodrug delivery—a noble approach in neurodegenerative disorder and glioblastoma

Keyphrases

• Central Nervous System 100%
• Glioblastoma 100%
• Blood-brain Barrier 100%
• Nanotechnology 100%
• Nanodrug 100%
• Nanocarriers 100%
• Neurodegenerative Disorders 100%
• Neuronal Damage 50%
• Alzheimer's Disease 50%
• Treatment Efficacy 50%
• Drug Interactions 50%
• Life-threatening 50%
• Parkinson's Disease 50%
• Neurological Disorders 50%
• Clinical Practice 50%
• Brain Regions 50%
• Liposomes 50%
• Healthcare 50%
• Chemotherapy 50%
• Active Ingredients 50%
• Therapeutic Efficacy 50%
• Public Health 50%
• Early Diagnosis 50%
• Viral Capsid 50%
• Patient Compliance 50%
• Nanocrystalline 50%
• Effective Treatment 50%
• Dendrimer 50%
• Adverse Drug Reaction 50%
• Brain Function 50%
• Recent Advancements 50%
• Huntington's Disease 50%
• Drug Delivery 50%
• Polymeric Nanoparticles 50%
• Drug Nanocarrier 50%
• Nanoplatform 50%
• Central Nervous System Delivery 50%
• Novel Disease 50%
• Metallic NPs 50%
• Neuroimmune Response 50%
• Silicon NPs 50%
• Alzheime's Disease 50%
• Drug Delivery Strategies 50%
• Multiple Drug Resistance 50%
• Nanoparticle Platform 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Nanocarrier 100%
• Glioblastoma 100%
• Diseases 100%
• Nanoparticle 66%
• Blood-Brain Barrier 66%
• Bioavailability 33%
• Prevalence 33%
• Liposome 33%
• Alzheimer's Disease 33%
• Adverse Drug Reaction 33%
• Parkinson's Disease 33%
• Drug Interaction 33%
• Drug Transport 33%
• Chemotherapy Regimens 33%
• Huntington Chorea 33%
• Nanocrystalline 33%
• Central Nervous System Drug 33%
• Dendrimer 33%
• Multidrug Resistance 33%